Articles

 Online First
The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth
By Al B. Benson III, MD; Robert W. Carlson, MD
March 2016, Vol 7, No 2
A recently published perspective in Value-Based Cancer Care criticized the National Comprehensive Cancer Network (NCCN) Evidence Blocks initiative. Regrettably, that perspective is extremely misleading and is full of innuendo and misuse of statistics.
Read More
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
By Lisa A. Raedler, PhD, RPh
Drug Updates
December 2015, Vol 6, No 11
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.
Read More
Two Studies Point to Inadequate Evidence Supporting Many FDA Drug Approvals
By Rosemary Frei, MSc
Health Policy, Policies & Guidelines
December 2015, Vol 6, No 11
Two related studies have documented significant deficiencies in the way the FDA approves expanded or new indications for drugs, using its expedited approval processes with limited evidence.
Read More

Page 173 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.